Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
Acquisition expands Merck’s growing hematology portfolio
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
The company had responded to the agency and carried out the required corrective actions.
The product is expected to be launched by Q4 FY23.
Subscribe To Our Newsletter & Stay Updated